Moleculin Biotech has filed a request with the FDA seeking accelerated review status for its drug candidate Annamycin as a treatment for relapsed/refractory acute myeloid leukemia.
Moleculin Bio seeks FDA's fast-track status for AML drug Annamycin
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.